SPEECH-PROCESSING
18.11.2015 10:09:46 CET | Business Wire | Press release
Speech Processing Solutions , the worldwide leader in professional dictation has received excellent reviews for its Philips SpeechMike Premium. The proven and almost indestructible dictation microphone offers users superior audio quality, coupled with unique antimicrobial housing and excellent ergonomics. The fully customizable dictation microphone saves time, increases efficiency and ultimately lowers costs for professionals across a variety of industry sectors.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151118005582/en/
The leader in healthcare
Philips SpeechMike has become a household name in many industries, particularly in the healthcare sector where the dictation microphone seamlessly integrates into leading healthcare IT systems. “It’s been a very reliable system for us. We’ve had great long-term success (…) I would highly recommend the SpeechMike Premium to any hospital with demanding dictation needs” explains Dave Baumgardner, Director of Information Management, Union Hospital in Dover, Ohio, USA.
Philips SpeechMike: A history of innovation
Speech Processing Solutions celebrated their 60th anniversary last year, driven by setting standards in the dictation industry by successful innovations. The original Philips SpeechMike was first launched in 1996. “The current top model, Philips SpeechMike Premium, is the result of almost two decades of attention to detail and striving for excellence through listening to customer’s needs from all over the world” explains Dr. Thomas Brauner, CEO of Speech Processing Solutions.
Made for speech recognition
Thanks to its special features such as the free floating microphone, the polished surface for non-sensitivity to touch noise, or the unique audio-optimized microphone grill, the Philips SpeechMike creates studio-like audio recordings . Together they successfully reduce unwanted surround sounds which enables two radiologists for example, to dictate simultaneously in one room without any interference. The clear recording levels enable the highest possible speech recognition accuracy. The dictation device is designed to work in perfect harmony with speech recognition software and has been awarded the highest possible Nuance speech recognition rating. This underlines Philips' position as global leader in audio competence, also underpinned by superior customer reviews.
Unlike many competitor products, the Philips SpeechMike offers exceptional features such as its antimicrobial housing, which is especially important in medical settings. The device fits perfectly into the hand where the ergonomic keyboard layout guarantees comfortable operation, even when dictating for several hours. Philips also carries out most extensive ‘stress tests’, making sure all devices are of exceptional quality, setting the benchmark in the dictation microphone industry. Dr. Thomas Brauner makes the point: “As our customers say: The best or nothing!”
For more information on the Philips SpeechMike please visit: www.philips.com/dictation
About Speech Processing Solutions
Speech Processing Solutions is the global number one in professional dictation. Founded in Austria in 1954 as part of Philips, the company has been the driving force in speech-to-text innovations for over 60 years. Always striving for excellence and putting emphasis on outstanding quality, the company has designed groundbreaking products, such as the portable Philips Pocket Memo voice recorder , the Philips SpeechMike Premium dictation microphone and the Philips SpeechExec dictation recorder app for smartphones. The latest innovation, Philips SpeechLive , makes dictation quicker and more convenient than ever before, by bringing secure dictation workflow to the cloud and enabling seamless speech-to-text with the new service Philips SpeechScribe. With solutions perfectly tailored to individual industry needs, Speech Processing Solutions has helped millions of satisfied customers around the globe save time and resources, allowing them to work as efficiently as possible.
Connect with Speech Processing Solutions on:
Facebook: http://www.facebook.com/philipsvoicetracer
Twitter @speech_com: http://www.twitter.com/speech_com
YouTube: http://www.youtube.com/philipsdictation
LinkedIn: http://www.linkedin.com/company/speech-processing-solutions
View source version on businesswire.com: http://www.businesswire.com/news/home/20151118005582/en/
./ContentItem/FormatPhilips SpeechMike Premium - the best or nothing
Contact:
Speech Processing Solutions
Richard Bancej
Richard.bancej@speech.com
Tel:
+43 1 60101-4191
www.philips.com/dictation
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
